Boston Scientific Pays More Than $1Bn For Lumenis’ Surgical Laser Business
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.
You may also be interested in...
Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions
During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.
The deal is the fourth major acquisition in the remote monitoring market in the last five weeks after Philips acquired BioTelemetry and Capsule and Hillrom bought Bardy Diagnostics.
Augmenix is the privately-held developer of SpaceOAR, an injected hydrogel spacer that is indicated for reducing collateral damage from radiation treatment for prostate cancer. It addresses a market worth about $750m, with total sales expected to reach $90m in 2019.